1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MM-398-07-03-01, NCT01494506
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000573370, UMDNJ-0120070076, 0120070076, NCT00553683
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 120 Sponsor: Other Protocol IDs: 2007-0910, NCT00769483
|
|
4.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: Neogenix 0901, NCT01040000
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CMEK162X2109, 2011-002578-21, NCT01449058
|
|
7.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PCRT 11-002, NCT01488552
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LCCC 2009-608, NCT01489865
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120111, 12-C-0111, NCT01583686
|
|
10.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 14453, I2H-MC-JWYD, NCT01632306
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000360863, UTHSC-MS-02117, NCT00082862
|
|
12.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000580812, UPCC-04206, GENENTECH-UPCC-04206, UPCC-805957, NCT00602602
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UFPTI 0609-PC01, NCT00685763
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UFPTI 0704-PC02, NCT00763516
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: KLT-PANC-001, NCT00733850
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: INST 0802, NCI-2011-02731, NCT00871169
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 011438, IND #103,981, 2008-437, NCT00881621
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0911010739, NCT01053013
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: PANC0007, SU-02012010-4843, 17073, NCT01146054
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 100166, 10-C-0166, NCT01174121
|
|
21.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI1738-09, NCT01188109
|
|
22.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01266, 10454, N01CM00070, R21CA149939, USCF-10454, 8598, NCT01222689
|
|
23.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: TRIO-TORI PA-01, NCI-2010-02190, NCT01234935
|
|
24.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02567, OSU 10045, CDR0000692060, N01CM00070, 8601, NCT01280058
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 114375, NCT01376310
|